Keyword Analysis & Research: baricitinib alopecia


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
baricitinib alopecia1.820.849342820
baricitinib0.970.765295311
alopecia1.030.43569138

Keyword Research: People who searched baricitinib alopecia also searched

Keyword CPC PCC Volume Score
baricitinib alopecia0.860.1799834
baricitinib alopecia areata1.460.6640227
baricitinib alopecia costo0.10.5462852
baricitinib alopecia price1.30.22383
baricitinib alopecia uk1.720.7212978
baricitinib alopecia nice0.470.2444486
baricitinib alopecia precio1.430.7831910
baricitinib alopecia results0.30.3123591
baricitinib alopecia australia1.141964773
baricitinib alopecia areata ema1.530.6625223
baricitinib alopecia areata fda0.840.111223
baricitinib alopecia side effects1.740.5452085
baricitinib alopecia areata phase 31.940.97929100
baricitinib alopecia ncbi1.910.9639452
baricitinib dose for alopecia areata0.880.1572014
baricitinib and alopecia areata1.491194773
eli lilly baricitinib alopecia1.120.759261
nejm baricitinib alopecia0.211680975

Search Results related to baricitinib alopecia on Search Engine

  • Two Phase 3 Trials of Baricitinib for Alopecia Areata | NEJM

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa2110343

    WEBMar 26, 2022 · In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.

    DA: 14 PA: 56 MOZ Rank: 1

  • FDA Approves First Systemic Treatment for Alopecia Areata

    fda.gov

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata

    WEBToday, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness...

    DA: 62 PA: 88 MOZ Rank: 72

  • Baricitinib for the treatment of alopecia areata in adults: Real …

    jaad.org

    https://www.jaad.org/article/S0190-9622(24)00100-2/fulltext

    WEBJan 19, 2024 · Alopecia areata (AA), characterized by immune-mediated hair loss without scarring, leads to substantial emotional distress because of high relapse rates despite conventional treatment in severe cases.1 Janus kinase (JAK) inhibitors target the JAK-STAT signaling pathway, reducing hair follicle inflammation.2 Baricitinib, an oral JAK1/JAK2 ...

    DA: 64 PA: 91 MOZ Rank: 33

  • Alopecia Areata Treatment | Olumiant® (baricitinib)

    lilly.com

    https://olumiant.lilly.com/alopecia-areata

    WEBAlopecia Areata Treatment | Olumiant® (baricitinib) Olumiant is a prescription medication that is a Janus kinase (JAK) inhibitor, and is used to treat adults with severe alopecia areata. Discover a once-daily pill for adults with severe alopecia areata. You could regrow your hair.

    DA: 15 PA: 86 MOZ Rank: 72

  • Efficacy and Safety of Baricitinib in Patients with Severe Alopecia

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974384/

    WEBMar 1, 2023 · The oral Janus kinase (JAK) inhibitor baricitinib has demonstrated efficacy for severe alopecia areata (AA) over 36 weeks. There are limited data on the longer-term treatment of AA. Objective.

    DA: 26 PA: 20 MOZ Rank: 58


  • Two Phase 3 Trials of Baricitinib for Alopecia Areata - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/35334197/

    WEBMar 26, 2022 · ClinicalTrials.gov/NCT03899259. In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. Longer trials are required to assess the efficacy and safety of baricitinib for alopecia areata.

    DA: 28 PA: 73 MOZ Rank: 6

  • Two Phase 3 Trials of Baricitinib for Alopecia Areata

    nejm.org

    https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110343

    WEBMar 26, 2022 · Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an...

    DA: 25 PA: 99 MOZ Rank: 23

  • Baricitinib in Alopecia Areata | New England Journal of Medicine

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMe2203440

    WEBMay 4, 2022 · Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international ...

    DA: 47 PA: 63 MOZ Rank: 48

  • Baricitinib for the Treatment of Alopecia Areata - PMC

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191081/

    WEBMay 17, 2023 · Baricitinib, an oral, reversible, selective JAK1/JAK2 inhibitor, was shown to be superior to placebo on hair growth after 36 weeks of treatment in adults with severe AA in a phase 2 trial and recently in two phase 3 trials (BRAVE-AA1 and BRAVE-AA2).

    DA: 33 PA: 72 MOZ Rank: 95

  • Treatment of severe alopecia areata with baricitinib - PMC

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818396/

    WEBOct 22, 2019 · This report of successful treatment of a patient with severe AA using the new JAK inhibitor, baricitinib, adds to the growing body of evidence showing efficacy not only of this class of medication as a whole, but also of JAK inhibitors of different specificities (eg, JAK1/2 vs JAK1/3) for AA.

    DA: 24 PA: 7 MOZ Rank: 78